Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19

Yardim, Meltem; Deniz, Levent; undefined, DAMLA; celik, nilufer; Ulas Kahya, Burcu

doi:10.56615/tkbd.2023.14

Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19

Meltem Yardım, (Yerköy Devlet Hastanesi, Tıbbi Biyokimya Bölümü, Yozgat, Türkiye)

Levent Deniz, (Sorgun Devlet Hastanesi, Tıbbi Biyokimya Bölümü, Yozgat, Türkiye)

Damla Kayalp, (Yozgat Şehir Hastanesi, Tıbbi Biyokimya Bölümü, Yozgat, Türkiye)

Nilüfer Çelik, (Dr. Behçet Uz Çocuk Hastanesi, Biyokimya Bölümü, İzmir, Türkiye)

Burcu Ulaş Kahya (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Türk Klinik Biyokimya Dergisi

2 1

Yıl: 2023 Cilt: 21 Sayı: 2 Sayfa Aralığı: 110 - 118 Metin Dili: İngilizce DOI: 10.56615/tkbd.2023.14 İndeks Tarihi: 09-01-2024

Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19

Öz:

Aim: It was aimed to determine predictive markers for the need for intensive care unit (ICU) hospitalization in patients with coronavirus infection. Material and Methods: This study was performed retrospectively from data of patients hospitalized with the diagnosis of Coronavirus 2019 (COVID-19) in Yerkoy State Hospital. A total of 170 patients with a laboratory diagnosis of coronavirus were included. Thorax computed tomography (CT) findings, hematologic data, liver and kidney function tests, lipid profiles, basal hormone data and some vitamin levels were assessed. Gender, age, and length of hospital stay were determined. The existence of an independent relationship between biochemical parameters and the risk of admission to the ICU was investigated by binary logistic regression analysis. Results: Mean age of participants was 69.12±13.72 years. 145 (85.3%) patients were discharged from the hospital with recovery, and 25 (14.7%) patients were referred to another hospital due to ICU needs. The median length of stay in the hospital was 5 (range 1-64) days. 143 (84.1%) patients had pathology in thorax CT. Length of stay in the hospital was significantly lower in referred patients than in non-ICU patients (p<0.001). Coronary artery disease (CAD) percentage was significantly higher in patients requiring ICU admission (p=0.010). We found no significant differences between non-ICU and ICU patients regarding age, sex, and CT findings. Platelet count (p=0.004) and monocyte percentage (p=0.018) were significantly lower, and Lactate Dehydrogenase (LDH) was significantly higher in patients requiring ICU p=0.007). Conclusion: The increase in LDH, decrease in platelet and monocyte, and presence of concomitant CAD in patients hospitalized with the diagnosis of COVID-19 may alert physicians regarding the need for ICU.

Anahtar Kelime: COVID-19 Intensive care unit LDH Hematological parameters

COVID-19'da Yoğun Bakıma Yatış Riskinin Belirlenmesinde Biyokimyasal Belirteçler

Öz:

Amaç: Korona virüs enfeksiyonu olan hastalarda yoğun bakım ünitesi (YBÜ) gereksinimi için prediktif belirteçlerin belirlenmesi amaçlandı. Gereç ve Yöntem: Bu çalışma, Yerköy Devlet Hastanesi'ne koronavirüs tanısı ile yatırılan hastaların verilerinden retrospektif olarak yapılmıştır. Çalışmaya COVID-19 tanılı toplam 170 hasta dahil edildi. Toraks bi lgisayarlı tomografi (BT), hematolojik veriler, karaciğer ve böbrek fonksiyon testleri, lipid profilleri, bazal hormon verileri ve bazı vitamin düzeyleri değerlendirildi. Cinsiyet, yaş ve hastanede kalış süreleri belirlendi. Biyokimyasal parametreler ile YBÜ yatış riski arasındaki bağımsız ilişkinin varlığı binary lojistik regresyon analizi ile araştırıldı. Bulgular: Hastaların ortalama yaşı 69,12±13,72 yıl idi. 145 (%85,3) hasta şifa ile hastaneden taburcu edildi, 25 (%14,7) hasta ise yoğun bakım ihtiyacı nedeniyle başka bir hastaneye sevk edildi. Hastanede ortalama kalış süresi 5 (1-64) gündü. 143 (%84,1) hastada toraks BT'de patoloji saptandı. Hastanede kalış süresi, sevk edilen hastalarda taburcu edilen hastalara göre anlamlı olarak daha düşük saptandı (p<0,001). Koroner arter hastalığı (KAH) yüzdesi yoğun bakım gereksinimi olan hastalarda anlamlı olarak yüksekti (p=0,010). Yoğun bakım gereksinimi olan ve olmayan hastalar arasında yaş, cinsiyet ve BT bulguları açısından anlamlı fark bulunmadı. Trombosit sayısı (p=0,004) ve monosit yüzdesi (p=0,018) YBÜ gereksinimi olan hastalarda anlamlı olarak düşük, Laktat Dehidrogenaz (LDH) anlamlı olarak yüksekti (p=0,007). Sonuç: COVID-19 tanısı ile yatırılan hastalarda LDH artışı, trombosit ve monositte azalma ve eşlik eden KAH varlığı yoğun bakım ihtiyacı açısından uyarıcı olabilir.

Anahtar Kelime: COVID-19 Yoğun bakım ünitesi LDH Hematolojik parametreler

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Celik O, Saglam A, Baysal B, Derwig IE, Celik N, Ak M, et al. Factors preventing materno-fetal transmission of SARS-CoV-2. Placenta 2020;97:1-5.
2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Groupfor Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-20.
3. Huang C, Wang Y, Li X,Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497-506.
4. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA 2020;323(21):2195-8.
5. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201(11):1430-4.
6. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605-10.
7. Carenzo L, Costantini E, Greco M, Barra FL, Rendiniello V, Mainetti M, et al. Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy. Anaesthesia 2020;75(7):928-34.
8. Celik O, Celik N, Aydin S, Baysal B, Aydin S, Saglam A, et al. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations. Cell Mol Biol (Noisy-le-grand) 2020;66(3):221-9.
9. Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol2020;92(9):1533-41.
10. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020;84:106504.
11. 11.Orhan B, Deniz L, Saglam ZA, Eren G, Inal BB. The effect of diagnostic value of biochemical parameters on mortality in COVID-19 patients. Med Science 2022;11(4):1511-5.
12. 12.Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY) 2020;12(12):11245-58.
13. Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta2020;509:135-8.
14. Pence BD. Severe COVID-19 and aging: are monocytes the key? GeroScience 2020;42:1051-61.
15. Gómez-Rial J, Rivero-Calle I, Salas A, Martinón-Tor- res F. Role of monocytes/macrophages in Covid-19 pathogenesis: implications for therapy. InfectDrug Re- sist 2020;13:2485-93.
16. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev 2020;7(6):998-1002.
17. Pirsalehi A, Salari S, Baghestani A, Sanadgol G, Shirini D, Baerz MM, et al. Differential alteration trend of white blood cells (WBCs) and monocytes count in severe and non-severe COVID-19 patients with in a 7-day follow-up. Iran J Microbiol 2021;13(1):8-16.
18. Sanchez-Cerrillo I, Landete P, Aldave B, San- chez-Alonso S, Sanchez-Azofra A, Marcos-Jimenez A, et al. Differential redistribution of activated monocyte and dendritic cell subsets to the lung as- sociates with severity of COVID-19. medRxiv 2020:10.1101/ 2020.05.13.20100925.
19. Kilercik M, Demirelce Ö, Serdar MA, Mikailova P, Serteser M. A newhaematocytometricindex: Predicting severity and mortality risk value in COVID-19 patients. PLoSOne 2021;16(8):e0254073.
20. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020;506:145-8.
21. D'Ecclesiis O, Gavioli C, Martinoli C, Raimondi S, Chiocca S, Miccolo C, et al. Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis. PLoS One 2022;17(7):e0268396.
22. Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A, Zumla A, et al. Immune responses during COVID-19 infection. Oncoimmunology 2020;9(1):1807836.
23. Mattioli F, Piva S, Stampatori C, Righetti F, Mega I, Peli E, et al. Neurologic and cognitive sequelae after SARS-CoV2 infection: Different impairment for ICU patients. J Neurol Sci 2022;432:120061.

APA	Yardim M, Deniz L, D, celik n, Ulas Kahya B (2023). Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. , 110 - 118. 10.56615/tkbd.2023.14
Chicago	Yardim Meltem,Deniz Levent, DAMLA,celik nilufer,Ulas Kahya Burcu Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. (2023): 110 - 118. 10.56615/tkbd.2023.14
MLA	Yardim Meltem,Deniz Levent, DAMLA,celik nilufer,Ulas Kahya Burcu Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. , 2023, ss.110 - 118. 10.56615/tkbd.2023.14
AMA	Yardim M,Deniz L, D,celik n,Ulas Kahya B Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. . 2023; 110 - 118. 10.56615/tkbd.2023.14
Vancouver	Yardim M,Deniz L, D,celik n,Ulas Kahya B Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. . 2023; 110 - 118. 10.56615/tkbd.2023.14
IEEE	Yardim M,Deniz L, D,celik n,Ulas Kahya B "Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19." , ss.110 - 118, 2023. 10.56615/tkbd.2023.14
ISNAD	Yardim, Meltem vd. "Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19". (2023), 110-118. https://doi.org/10.56615/tkbd.2023.14

APA	Yardim M, Deniz L, D, celik n, Ulas Kahya B (2023). Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. Türk Klinik Biyokimya Dergisi, 21(2), 110 - 118. 10.56615/tkbd.2023.14
Chicago	Yardim Meltem,Deniz Levent, DAMLA,celik nilufer,Ulas Kahya Burcu Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. Türk Klinik Biyokimya Dergisi 21, no.2 (2023): 110 - 118. 10.56615/tkbd.2023.14
MLA	Yardim Meltem,Deniz Levent, DAMLA,celik nilufer,Ulas Kahya Burcu Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. Türk Klinik Biyokimya Dergisi, vol.21, no.2, 2023, ss.110 - 118. 10.56615/tkbd.2023.14
AMA	Yardim M,Deniz L, D,celik n,Ulas Kahya B Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. Türk Klinik Biyokimya Dergisi. 2023; 21(2): 110 - 118. 10.56615/tkbd.2023.14
Vancouver	Yardim M,Deniz L, D,celik n,Ulas Kahya B Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19. Türk Klinik Biyokimya Dergisi. 2023; 21(2): 110 - 118. 10.56615/tkbd.2023.14
IEEE	Yardim M,Deniz L, D,celik n,Ulas Kahya B "Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19." Türk Klinik Biyokimya Dergisi, 21, ss.110 - 118, 2023. 10.56615/tkbd.2023.14
ISNAD	Yardim, Meltem vd. "Biochemical Markers in Determining the Risk of Intensive Care Unit Admission in COVID-19". Türk Klinik Biyokimya Dergisi 21/2 (2023), 110-118. https://doi.org/10.56615/tkbd.2023.14